Staging a play to address a timely need

Share this article:
The tragic shootings at Virginia Polytechnic Institute and State University in April underscored the need for education on diagnosing and treating mental health problems.

It was fitting, then, that Pri-Med and educational partner France Foundation in May rolled out the first of a series of national lectures in Norfolk, VA. In this newer version of an activity that began last year, actors are interviewed live by a physician to demonstrate the proper use of a mood disorder questionnaire (MDQ) in diagnosing bipolar disorder. Participants can ask questions during the sessions, funded by AstraZeneca.

“From a practical standpoint, [physicians] are literally witnessing how to go through the MDQ,” said Anne Goodrich, Pri-Med group director of physician insights.

The program dates to 2005, when the NIH found that 55% of Americans will develop a mental illness at some point in their lives. Pri-Med then conducted a study of physicians, finding education could have a positive impact.

Nearly 20,000 physicians completed the first round of lectures. Outcomes research showed improvements in competence and adherence to clinical standard.

The patient-interview format was phased in for 2007, and Goodrich said she hopes the role-playing scenario plus handouts and other resources given to audience members will help address remaining learning gaps.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...